Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Condition(s):ER-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:March 7, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):ER-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:March 7, 2024Recruiting
Condition(s):Breast CancerLast Updated:May 14, 2021Completed
Condition(s):Breast CancerLast Updated:April 18, 2023Recruiting
Condition(s):Advanced Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Breast Carcinoma; Cancer of the Breast; Cancer of Breast; Malignant Tumor of Breast; Breast TumorLast Updated:July 11, 2023Withdrawn
Condition(s):Stage IV (Metastatic) Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; PR-Positive Breast Cancer; HER2-negative Breast Cancer; Invasive Breast CancerLast Updated:August 1, 2023Withdrawn
Condition(s):Locally Advanced or Metastatic Breast CancerLast Updated:June 13, 2022Unknown status
Condition(s):Postmenopausal Women With ER+ HER2- Primary Breast CancerLast Updated:February 6, 2020Completed
Condition(s):Advanced Breast CancerLast Updated:December 5, 2023Active, not recruiting
Condition(s):Breast CancerLast Updated:November 30, 2020Recruiting
Condition(s):Breast CancerLast Updated:June 15, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.